2023-507910-28-00CompletedPhase 1
Safety, tolerability, pharmacokinetics and pharmacodynamics of ARV-102 in healthy participants
Source: EU CTIS (euclinicaltrials.eu) · Last updated 19 Jul 2024
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 96 (actual)
- First submitted
- 13 Nov 2023
- Start date
- 4 Jan 2024
- Lead sponsor
- Arvinas Operations Inc.
- EU CT number
- 2023-507910-28-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 96
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre for Human Drug Research | Leiden | Netherlands | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.